Video yükleniyor...
Video Yüklenemedi
Second T-TEER randomized trial: Tri-FR! Presented at #ESC2024 #ESCCongress2024 by Donal showing similar TRILUMINATE results: primary 1Yr endpoint driven by QoL but numerically lower mortality and HFH. Longer FU needed. European Society of Cardiology News European Society of Cardiology
11,978 görüntüleme • 1 yıl önce •via X (Twitter)
4 Yorum

David J. Cohen, MD, MSc1 yıl önce
@DonalErwan @ESCardioNews @escardio Nice to see replication of the QOL benefit that was seen in TRILUMINATE. Also noteworthy is the lack of benefit on other clinical endpoints (very low event rates with both GDMT or TTEER). @arnoldgehrke @psorajja

Donal1 yıl önce
@ESCardioNews @escardio Thanks @hahn_rt @CHURennes @vonBardelebenRS important to take care of the TR

Mathias Orban1 yıl önce
@DonalErwan @ESCardioNews @escardio Congrats to the authors. Now its up to TRICI-HF trial from @j_hausleiter @stolz_l @LMU_Uniklinikum to show maybe an effect on hard clinical endpoints.

Donal1 yıl önce
@ESCardioNews @escardio Thanks for sharing
